TOKYO--(BUSINESS WIRE)--Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company established by Forty51 ...
BASEL, Switzerland, Sept. 2, 2025 /PRNewswire/ -- Melodia Therapeutics, a Forty51 Ventures company, developing a next generation DPP1 inhibitor with best-in-class potential for inflammatory conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback